Acute and chronic sympathetic reflex activation and antihypertensive response to nifedipine

The importance of counterregulatory mechanisms triggered by arterial vasodilation for the antihypertensive response to the calcium entry blocking agent nifedipine was investigated in 13 men with mild to moderate essential hypertension. Blood pressure and systemic vascular resistance were significantly reduced 30 minutes after sublingual administration of 10 mg of nifedipine while heart rate, cardiac index and plasma norepinephrine concentrations increased (all p less than 0.01). Also, changes in mean blood pressure correlated inversely with arterial baroreflex sensitivity (r = -0.74, p less than 0.01), suggesting that arterial baroreflex mechanisms by means of sympathetic activation tend to limit the acute antihypertensive response. Blood pressure, but not systemic vascular resistance, decreased further (p less than 0.01) after 6 weeks of therapy with nifedipine 20 mg three times daily, while average heart rate, cardiac index and plasma norepinephrine concentrations had returned toward pretreatment values. Thus, a reduction of acutely increased sympathetic activity toward pretreatment values during long-term nifedipine therapy was associated with further decreases in blood pressure. The importance of sympathetic activity was also stressed by the finding of an inverse relation between chronic changes in heart rate and blood pressure (percent of control, r = -0.76, p less than 0.01). Blood volume did not change during long-term nifedipine therapy. The results suggest that the degree of sympathetic reflex activation in part determines the antihypertensive response to nifedipine monotherapy.

This article has been cited by other articles:

				S. F. Fernandez, M.-H. Huang, B. A. Davidson, P. R. Knight III, and J. L. Izzo Jr Modulation of Angiotensin II Responses in Sympathetic Neurons by Cytosolic Calcium Hypertension, January 1, 2003; 41(1): 56 - 63. [Abstract] [Full Text] [PDF]

				S. Richard, F. Leclercq, S. Lemaire, C. Piot, and J. Nargeot Ca2+ currents in compensated hypertrophy and heart failure Cardiovasc Res, February 1, 1998; 37(2): 300 - 311. [Abstract] [Full Text] [PDF]

				W. H. Frishman Mibefradil: A New Selective T-Channel Calcium Antagonist for Hypertension and Angina Pectoris Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(4): 321 - 330. [Abstract] [PDF]

				A. V. Chobanian Calcium Channel Blockers: Lessons Learned From MIDAS and Other Clinical Trials JAMA, September 11, 1996; 276(10): 829 - 830. [Abstract] [PDF]

				L. H. Opie and F. H. Messerli Nifedipine and Mortality : Grave Defects in the Dossier Circulation, September 1, 1995; 92(5): 1068 - 1073. [Full Text]

				S. Ogawa, G. Narita, H. Nomura, F. Yasuma, K. Miyaguchi, H. Hayashi, and I. Sotobata Effects of Vasodilators on Venous Tone in Vivo in Dogs Angiology, March 1, 1991; 42(3): 202 - 209. [Abstract] [PDF]

				Drugs Five Years Later: Nifedipine in Myocardial Ischemia, Systemic Hypertension, and Other Cardiovascular Disorders Ann Intern Med, November 1, 1986; 105(5): 714 - 729. [Abstract] [PDF]